- Home
- MTLS vs FDMT Comparison
MTLS vs FDMT Comparison
Compare MTLS & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTLS | FDMT |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.6M | 695.3M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MTLS | FDMT |
|---|---|---|
| Price | $7.64 | $13.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $31.71 |
| AVG Volume (30 Days) | 119.8K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | $6.38 | N/A |
| Revenue Next Year | $6.45 | $70.28 |
| P/E Ratio | $61.39 | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $4.78 | $6.47 |
| 52 Week High | $7.67 | $16.93 |
Technical Indicators
Market Signals| Indicator | MTLS | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 61.34 | 47.73 |
| Support Level | $6.37 | $8.43 |
| Resistance Level | $7.50 | $14.00 |
| Average True Range (ATR) | 0.27 | 0.92 |
| MACD | 0.06 | -0.26 |
| Stochastic Oscillator | 80.33 | 0.87 |
Price Performance
Historical ComparisonAbout MTLS Materialise NV
Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).